A first 4-biomarker panel consisting of IL-2Rα, TNFR1, IL-8, and HGF was validated for confirmation of aGVHD diagnosis and prediction of survival independent of GVHD severity (30). The gene discussed is HGF; the disease is graft versus host disease.